UNSPSC 51294421: Trazodone hydrochloride

This classification denotes an antidepressant agent with the molecular formula C19H22ClN5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6E8ZO8LRNM, chemically known as 1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)- but more generally known as trazodone hydrochloride, which bears US NIH Compound Identifier 5533. European Medicines Agency schedules Trazodone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15596MIG.

UNSPSC 51294421 Trazodone hydrochloride is a Commodity code that represents individual pharmaceutical products procured by state and local health agencies, though the recent opportunities tagged under this code show little direct activity for trazodone itself. Instead, the solicitations reflect broader state and local pharmaceutical procurement patterns: naloxone (opioid reversal), safe drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work under the code involves competitive bidding for pharmaceutical products with established National Drug Codes (NDCs), compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, maintenance of authorized wholesaler relationships, and adherence to federal and state pharmacy regulations including E-Verify certification and drug-free workplace policies.

Recent activity centers in Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with distribution through three authorized wholesalers and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as a market-intelligence tool exploring direct-to-manufacturer prescription programs for state employee health plans and self-insured group plans, signaling exploratory procurement activity upstream of formal competitive solicitations.